This company has been marked as potentially delisted and may not be actively trading.

Invitae (NVTA) Competitors

NVTA vs. LIFW, LIPO, ADTX, PTPI, and BACK

Should you be buying Invitae stock or one of its competitors? The main competitors of Invitae include MSP Recovery (LIFW), Lipella Pharmaceuticals (LIPO), Aditxt (ADTX), Petros Pharmaceuticals (PTPI), and IMAC (BACK). These companies are all part of the "medical" sector.

How does Invitae compare to MSP Recovery?

Invitae (NYSE:NVTA) and MSP Recovery (NASDAQ:LIFW) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

: Invitae has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500. Comparatively, MSP Recovery has a beta of -2.38, indicating that its stock price is 338% less volatile than the S&P 500.
: MSP Recovery has lower revenue, but higher earnings than Invitae. MSP Recovery is trading at a lower price-to-earnings ratio than Invitae, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Invitae $481.58M 0.00 -$3.11B -$5.38 N/A
MSP Recovery $10.73M 0.02 -$56.35M -$142.50 N/A
: In the previous week, MSP Recovery had 1 more articles in the media than Invitae. MarketBeat recorded 1 mentions for MSP Recovery and 0 mentions for Invitae. MSP Recovery's average media sentiment score of 0.71 beat Invitae's score of 0.00 indicating that MSP Recovery is being referred to more favorably in the news media.
Company Overall Sentiment
Invitae Neutral
MSP Recovery Positive
: 61.3% of Invitae shares are held by institutional investors. Comparatively, 3.8% of MSP Recovery shares are held by institutional investors. 0.7% of Invitae shares are held by insiders. Comparatively, 86.5% of MSP Recovery shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
: Invitae has a net margin of -299.14% compared to MSP Recovery's net margin of -906.67%. MSP Recovery's return on equity of -6.25% beat Invitae's return on equity.
Company Net Margins Return on Equity Return on Assets
Invitae -299.14% -6,100.71% -19.68%
MSP Recovery -906.67% -6.25% -2.39%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invitae	$481.58M	0.00	-$3.11B	-$5.38	N/A
MSP Recovery	$10.73M	0.02	-$56.35M	-$142.50	N/A

Company	Overall Sentiment
Invitae	Neutral
MSP Recovery	Positive

Company	Net Margins	Return on Equity	Return on Assets
Invitae	-299.14%	-6,100.71%	-19.68%
MSP Recovery	-906.67%	-6.25%	-2.39%

Summary

MSP Recovery beats Invitae on 7 of the 13 factors compared between the two stocks.

How does Invitae compare to Lipella Pharmaceuticals?

Lipella Pharmaceuticals (NASDAQ:LIPO) and Invitae (NYSE:NVTA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

: Lipella Pharmaceuticals has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Invitae has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500.
: Lipella Pharmaceuticals has higher earnings, but lower revenue than Invitae. Lipella Pharmaceuticals is trading at a lower price-to-earnings ratio than Invitae, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lipella Pharmaceuticals $536.36K 0.23 -$5.02M -$2.42 N/A
Invitae $481.58M 0.00 -$3.11B -$5.38 N/A
: In the previous week, Lipella Pharmaceuticals' average media sentiment score of 0.00 equaled Invitae'saverage media sentiment score.
Company Overall Sentiment
Lipella Pharmaceuticals Neutral
Invitae Neutral
: Invitae has a net margin of -299.14% compared to Lipella Pharmaceuticals' net margin of -988.83%. Lipella Pharmaceuticals' return on equity of -224.08% beat Invitae's return on equity.
Company Net Margins Return on Equity Return on Assets
Lipella Pharmaceuticals -988.83% -224.08% -172.88%
Invitae -299.14% -6,100.71% -19.68%
: 74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.3% of Invitae shares are owned by institutional investors. 32.1% of Lipella Pharmaceuticals shares are owned by company insiders. Comparatively, 0.7% of Invitae shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipella Pharmaceuticals	$536.36K	0.23	-$5.02M	-$2.42	N/A
Invitae	$481.58M	0.00	-$3.11B	-$5.38	N/A

Company	Overall Sentiment
Lipella Pharmaceuticals	Neutral
Invitae	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Lipella Pharmaceuticals	-988.83%	-224.08%	-172.88%
Invitae	-299.14%	-6,100.71%	-19.68%

Summary

Lipella Pharmaceuticals beats Invitae on 6 of the 11 factors compared between the two stocks.

How does Invitae compare to Aditxt?

Invitae (NYSE:NVTA) and Aditxt (NASDAQ:ADTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

: Invitae has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500. Comparatively, Aditxt has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500.
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Invitae
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Aditxt
1 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
: Aditxt has lower revenue, but higher earnings than Invitae. Invitae is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Invitae $481.58M 0.00 -$3.11B -$5.38 N/A
Aditxt N/A N/A -$41.71M -$11.10 thousand N/A
: In the previous week, Aditxt had 1 more articles in the media than Invitae. MarketBeat recorded 1 mentions for Aditxt and 0 mentions for Invitae. Invitae's average media sentiment score of 0.00 equaled Aditxt'saverage media sentiment score.
Company Overall Sentiment
Invitae Neutral
Aditxt Neutral
: Invitae has a net margin of -299.14% compared to Aditxt's net margin of -1,217,927.00%. Aditxt's return on equity of -374.60% beat Invitae's return on equity.
Company Net Margins Return on Equity Return on Assets
Invitae -299.14% -6,100.71% -19.68%
Aditxt -1,217,927.00% -374.60% -92.82%
: 61.3% of Invitae shares are owned by institutional investors. Comparatively, 15.5% of Aditxt shares are owned by institutional investors. 0.7% of Invitae shares are owned by company insiders. Comparatively, 0.0% of Aditxt shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invitae	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invitae	$481.58M	0.00	-$3.11B	-$5.38	N/A
Aditxt	N/A	N/A	-$41.71M	-$11.10 thousand	N/A

Company	Overall Sentiment
Invitae	Neutral
Aditxt	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Invitae	-299.14%	-6,100.71%	-19.68%
Aditxt	-1,217,927.00%	-374.60%	-92.82%

Summary

Invitae beats Aditxt on 7 of the 12 factors compared between the two stocks.

How does Invitae compare to Petros Pharmaceuticals?

Petros Pharmaceuticals (NASDAQ:PTPI) and Invitae (NYSE:NVTA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.

: Petros Pharmaceuticals has higher earnings, but lower revenue than Invitae. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Invitae, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Petros Pharmaceuticals $5.11M 0.04 -$8.16M -$39.69 N/A
Invitae $481.58M 0.00 -$3.11B -$5.38 N/A
: Petros Pharmaceuticals has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500. Comparatively, Invitae has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500.
: In the previous week, Petros Pharmaceuticals' average media sentiment score of 0.00 equaled Invitae'saverage media sentiment score.
Company Overall Sentiment
Petros Pharmaceuticals Neutral
Invitae Neutral
: 12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 61.3% of Invitae shares are held by institutional investors. 8.2% of Petros Pharmaceuticals shares are held by insiders. Comparatively, 0.7% of Invitae shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
: Petros Pharmaceuticals has a net margin of 0.00% compared to Invitae's net margin of -299.14%. Petros Pharmaceuticals' return on equity of -78.22% beat Invitae's return on equity.
Company Net Margins Return on Equity Return on Assets
Petros Pharmaceuticals N/A -78.22% -23.50%
Invitae -299.14% -6,100.71% -19.68%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11M	0.04	-$8.16M	-$39.69	N/A
Invitae	$481.58M	0.00	-$3.11B	-$5.38	N/A

Company	Overall Sentiment
Petros Pharmaceuticals	Neutral
Invitae	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
Invitae	-299.14%	-6,100.71%	-19.68%

Summary

Petros Pharmaceuticals beats Invitae on 6 of the 11 factors compared between the two stocks.

How does Invitae compare to IMAC?

IMAC (NASDAQ:BACK) and Invitae (NYSE:NVTA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

: IMAC has a net margin of 0.00% compared to Invitae's net margin of -299.14%. IMAC's return on equity of 0.00% beat Invitae's return on equity.
Company Net Margins Return on Equity Return on Assets
IMAC N/A N/A -325.44%
Invitae -299.14% -6,100.71% -19.68%
: IMAC has higher earnings, but lower revenue than Invitae. IMAC is trading at a lower price-to-earnings ratio than Invitae, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
IMAC $72.05K 2.00 -$9.42M -$3.12 N/A
Invitae $481.58M 0.00 -$3.11B -$5.38 N/A
: IMAC has a beta of 1.7, suggesting that its stock price is 70% more volatile than the S&P 500. Comparatively, Invitae has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500.
: In the previous week, IMAC's average media sentiment score of 0.00 equaled Invitae'saverage media sentiment score.
Company Overall Sentiment
IMAC Neutral
Invitae Neutral
: 5.8% of IMAC shares are held by institutional investors. Comparatively, 61.3% of Invitae shares are held by institutional investors. 12.3% of IMAC shares are held by company insiders. Comparatively, 0.7% of Invitae shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
IMAC	N/A	N/A	-325.44%
Invitae	-299.14%	-6,100.71%	-19.68%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IMAC	$72.05K	2.00	-$9.42M	-$3.12	N/A
Invitae	$481.58M	0.00	-$3.11B	-$5.38	N/A

Company	Overall Sentiment
IMAC	Neutral
Invitae	Neutral

Summary

IMAC beats Invitae on 7 of the 11 factors compared between the two stocks.

Get Invitae News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVTA vs. The Competition

Export

Metric	Invitae	Medical laboratories Industry	Medical Sector	NYSE Exchange
Market Cap	$80K	$6.47M	$6.22B	$22.95B
Dividend Yield	N/A	N/A	2.74%	4.03%
P/E Ratio	0.00	N/A	28.56	28.51
Price / Sales	0.00	2.87	535.58	14.51
Price / Cash	N/A	N/A	43.35	25.32
Price / Book	0.00	0.11	9.93	4.59
Net Income	-$3.11B	-$21.55M	$3.54B	$1.07B

Invitae Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVTA Invitae	N/A	$0.00 flat	N/A	N/A	$80K	$481.58M	N/A	1,700
LIFW MSP Recovery	N/A	$0.05 +6.6%	N/A	-99.7%	$299K	$10.73M	N/A	3	News Coverage Gap Down
LIPO Lipella Pharmaceuticals	N/A	$0.05 flat	N/A	-98.7%	$231K	$536.36K	N/A	4	High Trading Volume
ADTX Aditxt	0.8959 of 5 stars	$0.22 -12.2%	N/A	-100.0%	$230K	N/A	N/A	60	Upcoming Earnings Gap Down
PTPI Petros Pharmaceuticals	N/A	$0.01 +1.4%	N/A	-96.1%	$224K	$5.11M	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NVTA) was last updated on 5/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Invitae (NVTA) Competitors

NVTA vs. LIFW, LIPO, ADTX, PTPI, and BACK

How does Invitae compare to MSP Recovery?

Summary

How does Invitae compare to Lipella Pharmaceuticals?

Summary

How does Invitae compare to Aditxt?

Summary

How does Invitae compare to Petros Pharmaceuticals?

Summary

How does Invitae compare to IMAC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVTA vs. The Competition

Invitae Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Invitae (NVTA) Competitors

NVTA vs. LIFW, LIPO, ADTX, PTPI, and BACK

How does Invitae compare to MSP Recovery?

Summary

How does Invitae compare to Lipella Pharmaceuticals?

Summary

How does Invitae compare to Aditxt?

Summary

How does Invitae compare to Petros Pharmaceuticals?

Summary

How does Invitae compare to IMAC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVTA vs. The Competition

Invitae Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools